Lipogems Completes Patient Enrollment in Pivotal FDA Trial for Knee Osteoarthritis Treatment
核心洞察
Lipogems (搜索) has completed enrollment of 173 patients across 16 U.S. sites in the ARISE II clinical trial, evaluating MicroFat (搜索) injections for knee osteoarthritis (搜索) treatment.
The double-blinded, randomized controlled trial will assess pain reduction and functional improvement at 6 months post-injection, with results expected in late 2025.
The company is pursuing a modular Premarket Approval Application (PMA) with the FDA, aiming to secure specific indication for knee OA and expand treatment accessibility through reimbursement.
Lipogems (搜索) has reached a significant milestone in its pursuit of expanding treatment options for knee osteoarthritis (搜索), announcing the completion of patient enrollment in its ARISE II U.S. FDA IDE Study. The trial, which recruited 173 participants across 16 prestigious U.S. medical centers in just 9 months, aims to evaluate the efficacy and safety of MicroFat (搜索) injections compared to saline controls.
The double-blinded, randomized controlled study represents the company's largest clinical trial to date, focusing on measuring improvements in pain and function at 6 months following treatment. This research builds upon the existing FDA clearance of the Lipogems (搜索) device, which has been approved for orthopaedic and arthroscopic surgery applications in lipoaspirate tissue processing for the past decade.
Clinical Significance and Market Need
"With an aging population and more individuals at risk, we are excited to provide Lipogems (搜索) as a treatment option for patients that are not ready or do not qualify for a knee replacement," stated Dr. Martin Roche, Director of Arthroplasty and Robotics at Hospital for Special Surgery. "We are confident these studies will prove that Lipogems will not only help improve pain and function but also positively impact the patient's quality of life so they can enjoy their families, sports, and hobbies."
Regulatory Strategy and Market Access
The ARISE I and II studies form part of Lipogems (搜索)' comprehensive strategy to secure a specific indication for knee osteoarthritis (搜索) treatment. Carl Llewellyn, Chief Executive Officer of Lipogems USA, emphasized the company's commitment to expanding treatment accessibility: "As a responsible company, the goal of these studies is to prove the efficacy of Lipogems for this patient population and ultimately apply and obtain reimbursement for this indication."
The company has already initiated the modular Premarket Approval Application (PMA) process following FDA confirmation, marking a crucial step toward potential commercialization. This regulatory pathway could significantly impact treatment options for patients who have experienced limited relief from conservative treatments but are not yet candidates for knee replacement surgery.
Technology Platform and Global Presence
Lipogems (搜索)' proprietary technology involves closed-loop processing and transfer of lipoaspirate tissue, offering a novel approach to orthopedic treatment. The company maintains a strong international presence, with its products available in 29 countries, demonstrating its commitment to global healthcare innovation and patient care.
The anticipated release of the ARISE II trial results in late 2025 could potentially reshape the treatment landscape for knee osteoarthritis (搜索), offering a new option in the continuum of care between conservative management and joint replacement surgery.